 |
answer text |
<p>The Accelerated Access Collaborative (AAC) is interested in supporting the most
strategically important products that will have the biggest impact on patient health
outcomes and delivery of National Health Service services.</p><p>When selecting products,
the AAC will consider the following irrespective of innovation type (i.e. medicines,
diagnostic tools, and digital products):</p><p>- evidence of clinical and cost effectiveness;</p><p>-
addressing significant unmet need;</p><p>- application to large populations or high
budget impact; and</p><p>- enabling a novel mode of action or enabling significant
changes to the care pathway.</p><p>Further information is available at the following
link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p><p>
</p><p> </p>
|
 |
